Product Description
RAPA-501 is being developed by Rapa Therapeutics for the treatment of Amyotrophic Lateral Sclerosis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04220190?term=RAPA-501&draw=2&rank=1)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rapa Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RAPA-501-ALS | P3 |
Recruiting |
Amyotrophic Lateral Sclerosis |
2026-07-01 |